Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

ISSN

2374-2437

Date Issued

2020

Author(s)

Joensuu, Heikki

Eriksson, Mikael

Sundby Hall, Kirsten

Reichardt, Annette

Hermes, Barbara

Schütte, Jochen

Cameron, Silke

Hohenberger, Peter

Jost, Philipp J.

Al-Batran, Salah-Eddin

Lindner, Lars H.

Bauer, Sebastian

Wardelmann, Eva

Nilsson, Bengt

Kallio, Raija

Jaakkola, Panu

Junnila, Jouni

Alvegård, Thor

Reichardt, Peter

DOI

10.1001/jamaoncol.2020.2091